单细胞分析揭示复发/难治性急性髓系白血病化疗诱导的细胞重编程及新治疗靶点
研究利用单细胞RNA测序分析原发难治或短期复发急性髓系白血病患者骨髓样本,发现静息态干样细胞(QSCs)参与化疗耐药和不良预后,化疗中增殖态干/祖样细胞(PSPs)重编程获得QSC样表达模式并上调CD52和LGALS1,LGALS1抑制剂可清除QSCs并增强化疗效果。
要点
- 静息态干样细胞(QSCs)与急性髓系白血病化疗耐药和不良结局相关。
- 化疗中增殖态干/祖样细胞重编程为QSC样表达模式,上调CD52和LGALS1。
- LGALS1抑制剂可清除QSCs并增强化疗对原发白血病细胞和异种移植模型的效果。
核心结论
- 静息态干样细胞(QSCs)参与急性髓系白血病化疗耐药和不良结局,化疗中增殖态干/祖样细胞(PSPs)重编程获得QSC样表达模式。
- LGALS1是化疗耐药急性髓系白血病的潜在靶点,LGALS1抑制剂有助于清除QSCs并增强化疗效果。
研究设计与样本
- 研究采用单细胞RNA测序(scRNA-seq)分析原发难治或短期复发急性髓系白血病患者骨髓样本的细胞状态和转录组肿瘤内异质性。
- 研究进行了纵向scRNA-seq分析、流式细胞术分析,并在患者来源原发急性髓系白血病细胞、细胞系和急性髓系白血病异种移植模型中验证LGALS1抑制剂的作用。
主要发现
- 与增殖态干/祖样细胞(PSPs)相比,静息态干样细胞(QSCs)亚群参与急性髓系白血病化疗耐药和不良 outcomes。
- 纵向scRNA-seq分析显示,难治性急性髓系白血病患者化疗期间PSPs重编程获得QSC样表达模式,以CD52和LGALS1表达上调为特征。
- 流式细胞术分析证实,诊断时存在的CD99+CD49d+CD52+Galectin-1+(QSCs)细胞与化疗耐药相关,并在难治患者残留急性髓系白血病细胞中进一步富集。
- QSCs与单核细胞之间CD52-SIGLEC10相互作用可能促进免疫逃逸和不良 outcomes。
- LGALS1抑制剂有助于清除QSCs并增强化疗在患者来源原发急性髓系白血病细胞、细胞系和急性髓系白血病异种移植模型中的效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chemoresistance and relapse are the leading cause of AML-related deaths. Utilizing single-cell RNA sequencing (scRNA-seq), we dissected the cellular states of bone marrow samples from primary refractory or short-term relapsed AML patients and defined the transcriptional intratumoral heterogeneity. We found that compared to proliferating stem/progenitor-like cells (PSPs), a subpopulation of quiescent stem-like cells (QSCs) were involved in the chemoresistance and poor outcomes of AML. By performing longitudinal scRNA-seq analyses, we demonstrated that PSPs were reprogrammed to obtain a QSC-like expression pattern during chemotherapy in refractory AML patients, characterized by the upregulation of CD52 and LGALS1 expression. Flow cytometric analysis further confirmed that the preexisting CD99+CD49d+CD52+Galectin-1+ (QSCs) cells at diagnosis were associated with chemoresistance, and these cells were further enriched in the residual AML cells of refractory patients. Interaction of CD52-SIGLEC10 between QSCs and monocytes may contribute to immune evading and poor outcomes. Furthermore, we identified that LGALS1 was a promising target for chemoresistant AML, and LGALS1 inhibitor could help eliminate QSCs and enhance the chemotherapy in patient-derived primary AML cells, cell lines, and AML xenograft models. Our results will facilitate a better understanding of the AML chemoresistance mechanism and the development of novel therapeutic strategies for relapsed/refractory AML patients.
引用
- Li K, Du Y, Cai Y, et al. Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia. Leukemia. 2022. PMID: 36543880. doi:10.1038/s41375-022-01789-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。